1-6 of 6
Fabian Frontzek
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

Fabian Frontzek, Loïc Renaud, Ulrich Duehrsen, Viola Poeschel, Sophie Bernard, Loïc Chartier, Nicolas Ketterer, Christian Recher, Olivier Fitoussi, Gerhard Held, Rene-Olivier Casasnovas, Corinne Haioun, Nicolas Mounier, Hervé Tilly, Franck Morschhauser, Steven Le Gouill, Imke E. Karsten, Gerben Duns, Christian Steidl, David W. Scott, Wolfram Klapper, Andreas Rosenwald, German Ott, Thierry Jo Molina, Georg Lenz, Marita Ziepert, Bettina Altmann, Catherine Thieblemont, Norbert Schmitz
Journal: Blood
Blood (2023) 142 (Supplement 1): 71.
https://doi.org/10.1182/blood-2023-178815
Published: 2023
Journal Articles

Lymphomagenic Roles of MYC, E2F and Mir-150-5p in Plasmablastic Lymphoma: Therapeutic and Prognostic Implications

Miriam Verdú Bou, Maria Joao Baptista, Aleix Mendez Lopez, Gustavo Tapia, Marcelo Lima Ribeiro, Gaël Roué, Jose Luis Mate, Pau Abrisqueta, Mariana Bastos-Oreiro, Miguel Alcoceba, Eva González Barca, Fina Climent, Antonio Salar, Juan-Manuel Sancho, Fabian Frontzek, Annette M. Staiger, German Ott, Manuel Castro De Moura, Georg Lenz, Jose Tomas Navarro
Journal: Blood
Blood (2022) 140 (Supplement 1): 9266–9268.
https://doi.org/10.1182/blood-2022-168552
Published: 2022
Journal Articles

Tackling ALK-positive LBCL

Clinical Trials & Observations
Fabian Frontzek, Georg Lenz
Journal: Blood
Blood (2022) 140 (16): 1751–1752.
https://doi.org/10.1182/blood.2022017742
Published: 2022
Journal Articles

CNS prophylaxis in DLBCL: time to say goodbye?

Norbert Schmitz, Fabian Frontzek
Journal: Blood
Blood (2022) 139 (3): 315–317.
https://doi.org/10.1182/blood.2021014043
Published: 2022
Journal Articles

Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA)

Fabian Frontzek, MD, Marita Ziepert, PhD, Maike Nickelsen, Bettina Altmann, PhD, Bertram Glass, Mathias Haenel, MD, Lorenz Truemper, MD PhD, Gerhard Held, MD, Martin Bentz, MD, Peter Borchmann, MD, Martin Dreyling, MD, Andreas Viardot, Professor Dr, Frank P. Kroschinsky, MDMBA, Bernd Metzner, MDPhD, Annette M. Staiger, PhD, Heike Horn, PhD, German Ott, MD, Andreas Rosenwald, MD, Markus Loeffler, MD, Georg Lenz, Norbert Schmitz, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-138412
Published: 2020
Journal Articles

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Fabian Frontzek, MD, Marita Ziepert, PhD, Maike Nickelsen, Bettina Altmann, PhD, Bertram Glass, Mathias Hänel, MD, Lorenz Truemper, MD, Gerhard Held, MD, Martin Bentz, MD, Peter Borchmann, MD, Martin H. Dreyling, MD PhD, Andreas Viardot, MD PhD, Frank P. Kroschinsky, MDMBA, Bernd Metzner, MD PhD, Annette M. Staiger, PhD, Heike Horn, PhD, German Ott, MD, Andreas Rosenwald, MD, Markus Loeffler, MD, Georg Lenz, MD, Norbert Schmitz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1589.
https://doi.org/10.1182/blood-2019-123637
Published: 2019